These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7690505)

  • 1. Neutralizing epitopes of African horsesickness virus serotype 4 are located on VP2.
    Burrage TG; Trevejo R; Stone-Marschat M; Laegreid WW
    Virology; 1993 Oct; 196(2):799-803. PubMed ID: 7690505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and characterization of the two outer capsid proteins of African horsesickness virus: the role of VP2 in virus neutralization.
    Martinez-Torrecuadrada JL; Iwata H; Venteo A; Casal I; Roy P
    Virology; 1994 Jul; 202(1):348-59. PubMed ID: 8009847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a linear neutralization domain in the protein VP2 of African horse sickness virus.
    Martínez-Torrecuadrada JL; Casal JI
    Virology; 1995 Jul; 210(2):391-9. PubMed ID: 7542417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenic profile of African horse sickness virus serotype 4 VP5 and identification of a neutralizing epitope shared with bluetongue virus and epizootic hemorrhagic disease virus.
    Martínez-Torrecuadrada JL; Langeveld JP; Venteo A; Sanz A; Dalsgaard K; Hamilton WD; Meloen RH; Casal JI
    Virology; 1999 May; 257(2):449-59. PubMed ID: 10329555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of antigenic regions on VP2 of African horsesickness virus serotype 3 by using phage-displayed epitope libraries.
    Bentley L; Fehrsen J; Jordaan F; Huismans H; du Plessis DH
    J Gen Virol; 2000 Apr; 81(Pt 4):993-1000. PubMed ID: 10725425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge.
    Roy P; Bishop DH; Howard S; Aitchison H; Erasmus B
    J Gen Virol; 1996 Sep; 77 ( Pt 9)():2053-7. PubMed ID: 8811002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7.
    Martínez-Torrecuadrada JL; Díaz-Laviada M; Roy P; Sánchez C; Vela C; Sánchez-Vizcaíno JM; Casal JI
    J Gen Virol; 1996 Jun; 77 ( Pt 6)():1211-21. PubMed ID: 8683209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4.
    Stone-Marschat MA; Moss SR; Burrage TG; Barber ML; Roy P; Laegreid WW
    Virology; 1996 Jun; 220(1):219-22. PubMed ID: 8659117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production and properties of monoclonal antibodies against African horsesickness virus, serotype 3.
    Van Wyngaardt W; Du Plessis DH; Van Wyngaardt S; Verschoor JA
    Onderstepoort J Vet Res; 1992 Jun; 59(2):129-33. PubMed ID: 1513593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformation of the VP2 protein of bluetongue virus (BTV) determines the involvement in virus neutralization of highly conserved epitopes within the BTV serogroup.
    White JR; Eaton BT
    J Gen Virol; 1990 Jun; 71 ( Pt 6)():1325-32. PubMed ID: 1693664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.
    Guthrie AJ; Quan M; Lourens CW; Audonnet JC; Minke JM; Yao J; He L; Nordgren R; Gardner IA; Maclachlan NJ
    Vaccine; 2009 Jul; 27(33):4434-8. PubMed ID: 19490959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic methods for African horsesickness virus using monoclonal antibodies to structural and non-structural proteins.
    Ranz AI; Miguet JG; Anaya C; Venteo A; Cortés E; Vela C; Sanz A
    Vet Microbiol; 1992 Nov; 33(1-4):143-53. PubMed ID: 1481354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and localization of a serotypic neutralization determinant on the VP2 protein of bluetongue virus 13.
    Hwang GY; Li JK
    Virology; 1993 Aug; 195(2):859-62. PubMed ID: 7687805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
    Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J
    Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A complex neutralization domain of bluetongue virus serotype 17 defines a virulence-associated marker.
    Bernard KA; Israel BA; Schultz KT
    Viral Immunol; 1996; 9(2):97-106. PubMed ID: 8822626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing epitopes of the serotypes of bluetongue virus present in the United States.
    Rossitto PV; MacLachlan NJ
    J Gen Virol; 1992 Aug; 73 ( Pt 8)():1947-52. PubMed ID: 1379625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homotypic and heterotypic neutralization determinants of bluetongue virus serotype 17.
    Pierce CM; Rossitto PV; MacLachlan NJ
    Virology; 1995 May; 209(1):263-7. PubMed ID: 7538255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. African horsesickness virus VP7 sub-unit vaccine protects mice against a lethal, heterologous serotype challenge.
    Wade-Evans AM; Pullen L; Hamblin C; O'Hara R; Burroughs JN; Mertens PP
    J Gen Virol; 1997 Jul; 78 ( Pt 7)():1611-6. PubMed ID: 9225037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cloning, sequencing and expression of the gene that encodes the major neutralisation-specific antigen of African horsesickness virus serotype 9.
    Venter M; Napier G; Huismans H
    J Virol Methods; 2000 Apr; 86(1):41-53. PubMed ID: 10713375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definition of neutralizing sites on African horse sickness virus serotype 4 VP2 at the level of peptides.
    Martínez-Torrecuadrada JL; Langeveld JPM; Meloen RH; Casal JI
    J Gen Virol; 2001 Oct; 82(Pt 10):2415-2424. PubMed ID: 11562535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.